NeuroScientific Biopharmaceuticals hits record low on clinical trial rejection

Neuroscientific Biopharmaceuticals

07/09/2022 07:07

** Shares of Australia's NeuroScientific Biopharmaceuticals
Ltd  NSB.AX  fall as much as 61.4% to all-time low of A$0.083
    ** NSB says pharmaceutical regulator Human Research Ethics
Committee (HREC) rejected co's planned phase I clinical trial
for the drug EmtinB  urn:newsml:reuters.com:*:nASX2X2mRR 
    ** Co previously said EmtinB reduces key drivers of chronic
inflammation and autoimmune diseases 
    ** HREC determined that at this stage, NSB's supporting
documentation did not sufficiently address risk-benefit profile
to justify conduct of planned phase I clinical trial - co 
    ** Co posts biggest intraday pct fall of all time 
    ** Shares are down 35.8% YTD, as of last close 
    

 (Reporting by John Biju)
 ((John.Biju@thomsonreuters.com;))